In today’s episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therapeutic potential. The episode features three biotech companies developing DMT therapies: Algernon, Psilera, and Pharmadrug.
In this episode, we discuss:
- DMT therapies for organ transplants, stroke patients and substance abuse disorders
- Research supporting NN-DMT’s antioxidative and anti-inflammatory effects and the receptors it targets
- Being a private company vs. public company in psychedelics
NN-DMT
5-MeO-DMT
Bioavailability
DMT transdermal patch
Sigma-1
Donepezil
Dr. Rick Strassman
Angiogenesis
Orphan Drug Designation
Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh
Read the transcript here.
Find us at businesstrip.fm
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional music: Copley Beat by Blue Dot Sessions, Simplify by Little Glass Men, Pedalrider by Blue Dot Sessions, Running Waters by Jason Shaw, and Neon Drip by Blue Dot Sessions